Project Grant R01HL181016
Award Date 8/18/25
Completion Date 5/31/29
Dollars Obligated $759K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $834,249 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comparative study of clinical outcomes, patient experiences, and mechanistic insights between transcatheter and surgical treatment of degenerative mitral regurgitation (DMR). The study aims to provide long-term data on clinical effectiveness, safety, and patient-reported outcomes to inform treatment selection and guide patient care. It will also utilize...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) totaling $699,133 provides funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key objectives are to: Measure transcription, chromatin accessibility, and histone modifications in the heart, kidney, and liver to map the...
- This federal Project Grant award of $757,555 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Cedars-Sinai Medical Center to develop and validate a fast, robust quantitative susceptibility mapping (QSM) MRI method for accurate quantification of iron deposition in hemorrhagic myocardial infarction. The research aims to address technical limitations with the current standard cardiac iron imaging approach (R2* MRI), enabling more...
- This federal Project Grant award of $777,258 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance the understanding of heart failure in hypertrophic cardiomyopathy (HCM) through the use of cardiac magnetic resonance imaging (CMR). The grant will support research by the Beth Israel Deaconess Medical Center, Inc. (BIDMC) to characterize the key pathophysiologic mechanisms of heart failure symptoms in HCM and evaluate the effects of the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $811,885 in funding to the J. David Gladstone Institutes in San Francisco, California. The award supports research to investigate the epigenomic mechanisms governing cardiac fibrosis and heart failure pathogenesis. Key goals include understanding the role of the MEOX1 transcriptional regulator in fibroblast activation and fibrosis, with...
- This federal Project Grant award, valued at $735,838.00 and awarded on July 15, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports research into the role of hexokinase 1 (HK1) mitochondrial binding and its impact on cardiac endothelial cell function and the development of heart failure with preserved ejection fraction (HFpEF). The research, to be conducted by the University of Arizona, aims to address the fundamental gap in...
- This $612,186 Project Grant, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports research at the University of Iowa to investigate the role of lysosomal dysfunction in the pathogenesis of heart failure with preserved ejection fraction (HFPEF). The research project aims to determine how disruption of cardiac immuno-metabolic homeostasis by lysosomal dysfunction, specifically related to the lysosomal reductase gamma interferon-inducible...
- This federal Project Grant award of $131,085 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to elucidate the cardiac protective mechanisms of SGLT2 inhibitors, a class of drugs originally developed to treat diabetes. The five-year research plan leverages human induced pluripotent stem cell-derived cardiovascular cells, single-cell RNA sequencing, metabolomics, and large-scale drug-protein interaction determination to test the hypothesis...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $549,796 to Cedars-Sinai Medical Center to conduct research on the regulation of cardiac metabolism during leukemia. The project aims to examine how somatic mutations in acute myeloid leukemia (AML) impact oxidative metabolism in the heart, leading to structural remodeling and heart failure. Key objectives include investigating...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...